Neumora Therapeutics (NMRA)

• Market cap: $150M
• 1 day: -7.63%
• 5 days: -18.97%
• 1 month: -34.49%
• 3 months: -53.11%
• 6 months: -93.16%
• Year to date: -53.11%
• 1 year: -93.37%
• 5 years: -94.32%
• 10 years: -94.32%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

221% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 14

29% more funds holding

Funds holding: 103 [Q3] → 133 (+30) [Q4]

26% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 31

6.84% more ownership

Funds ownership: 42.89% [Q3] → 49.72% (+6.84%) [Q4]

4% more call options, than puts

Call options by funds: $64.8M | Put options by funds: $62.2M

6% less capital invested

Capital invested by funds: $906M [Q3] → $852M (-$54.8M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 117% upside
• Avg. target: $7.20 679% upside
• High target: $18 1,849% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Stifel Paul Matteis 38% 1-year accuracy 6 / 16 met price target	117% upside $2	Hold Downgraded	7 Mar 2025
HC Wainwright & Co. Douglas Tsao 23% 1-year accuracy 40 / 173 met price target	1,849% upside $18	Buy Reiterated	7 Mar 2025
RBC Capital Brian Abrahams 20% 1-year accuracy 14 / 70 met price target	333% upside $4	Sector Perform Reiterated	4 Mar 2025
Needham Ami Fadia 29% 1-year accuracy 50 / 171 met price target	441% upside $5	Buy Reiterated	4 Mar 2025
B of A Securities Geoff Meacham 59% 1-year accuracy 20 / 34 met price target	658% upside $7	Buy Maintained	6 Jan 2025